Stress is known as a major risk factor for cardiovascular morbidity and mortality since the
novel cardiac syndrome tako-tsubo cardiomyopathy, also known as stress cardiomyopathy …

Neuropeptide Y (NPY) is thought to be co-released with catecholamines in response to
major cardiovascular stresses, but its relation to the release of catecholamines in response …

In their recently published article, Szardien et al. reported a 78-year-old female patient who
had suffered stress cardiomyopathy (SCM) accompanied by increased serum levels of …

Hypertension-induced left ventricular hypertrophy (LVH), along with ischemic heart disease,
result in LV remodeling as part of a continuum that often leads to congestive heart failure …

The relationship among neuropeptide Y (NPY), catecholamines and haemodynamics was
assessed both at baseline and during inotropic intervention in patients with congestive heart …

Abstract purpose: Our objectives were to assess whether plasma neuropeptide Y (NPY)
levels are elevated in patients with congestive heart failure (CHF) and whether or not NPY …

Neuropeptide Y (NPY) is coreleased with the classical transmitter noradrenaline in both the
peripheral and central nervous systems, and has been shown to potentiate the pressor …

Neuropeptide Y (NPY), a putative sympathetic neurotransmitter and neuromodulator, is
released during sympathetic nerve stimulation and causes vasoconstriction and …

Abstract Aims Neuropeptide Y (NPY) is a potent vasoconstrictor released during sympathetic
activation that may be involved in myocardial ischaemia. We examined the effect of a Y1 …

Publisher Summary This chapter focuses on the attempts to further characterize the
relationship of NPY to NE release under physiological and pathophysiological conditions …